INTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is a hematopoietic stem cell disorder characterized by intravascular hemolysis due to the absence of the GPI-anchored complement regulatory proteins CD55 and CD59. CD59 blocks the formation of the terminal complement complex (the membrane-attack complex) on the cell surface, thereby preventing erythrocyte lysis and in vitro platelet activation. Affected red blood cells are rendered sensitive to complement-mediated lysis leading to free hemoglobin release.
(1) Chronically, and during severe bouts of hemolysis (paroxysms), hemoglobin can saturate biochemical systems resulting in hemoglobinuria. Excessive or persistent intravascular hemolysis in patients with PNH causes anemia, hemoglobinuria and complications related to the presence of plasma free hemoglobin, including abdominal pain, dysphagia, erectile dysfunction, possibly pulmonary hypertension and chronic kidney disease, and most importantly venous and arterial thrombosis. (2) Possible mechanisms include:
-procoagulant microparticles released by complement-mediated platelet activation, (8) -chronic hypofibrinolysis through altered plasminogen activation, possibly due to a decrease in urinary-plasminogen activator receptor (u-PAR) expression on leukocyte surfaces, (9, 10) -release of free hemoglobin by chronic hemolysis, leading to nitric oxide (NO) depletion and, subsequently, endothelial dysfunction and platelet activation. (11, 12) Primary or secondary prophylaxis with anticoagulants, vitamin-K antagonists (VKA) or low molecular weight heparin (LMWH), carries a high risk of complications and is insufficient to prevent thrombosis in this setting. (13) 
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Arterial thrombosis and venous thromboembolism (VTE) are potentially lifethreatening complications of PNH (3) and are the leading cause of death in this disease. (4) VTE in critical anatomic sites (cerebral and splanchnic circulation) is major cause of morbidity and mortality in PNH. Retrospective studies have suggested that the risk of thrombosis might correlate with the size of the PNH granulocyte clone. (5) Thrombosis has been reported in patients without overt evidence of hemolysis, with smaller clones, mild anemia and no transfusions. (6, 7) The etiology of the increased thrombotic risk in patients with PNH is unclear.
Eculizumab, a humanized antibody that blocks cleavage of the complement component C5, thereby preventing complement-mediated RBC lysis, (14) has been shown to reduce intravascular hemolysis, hemoglobinuria, and transfusion requirements, (15) with an associated improvement in the quality of life of patients with PNH. Other benefits include less chronic kidney disease, (16) and pulmonary hypertension. (17) Eculizumab also prevents thrombosis in PNH. (13) The purpose of this study was to examine the potential contributions of activation of the coagulation and/or fibrinolysis systems, and activation of the vascular endothelial cell surface, to the prothrombotic state in patients with PNH. Additionally, to show the modifications of these systems in PNH, will help to better understand the mechanisms by which eculizumab prevents clinical thrombosis.

DESIGN AND METHODS
Study design
From January 2007 to August 2008, PNH patients who started to receive eculizumab for a hemolytic form of PNH were enrolled in the 10 French centers.
Eculizumab was given by intravenous infusion as follows: an induction phase with a dose of 600 mg every 7 days for a total of 4 doses; then 900 mg 7 days later; followed by a maintenance phase with a dose of 900 mg every 14±2 days, as previously described. (15) Blood collection and plasma preparation
Three venous blood samples were collected atraumatically from each patient after an overnight fast. Blood was collected in 3.2% sodium citrate at baseline, once just prior to eculizumab infusion, once at week 5 just before the first dose of 900 mg, and once at week 11 ± 2, during eculizumab maintenance treatment. Platelet-poor plasma was prepared within two hours by two centrifugation steps at 2500 g for 15 min at 15°C, then aliquoted and stored at 80°C until testing. All samples were tested by the same laboratory, and one aliquot of each plasma sample was thawed at 37°C immediately before the assay. A control group of 30 healthy blood donors was used to determine the normal range of endothelial microparticles.
The procedures were conducted in accordance with the Helsinki Declaration of 1975, as revised in 2000, and all participants gave their informed consent. The study was approved by the IRB of Saint Louis Hospital, Paris, France. were measured with a STAR analyzer, using an immuno-turbidimetric assay (STA® Liatest®; Diagnostica Stago, Asnières, France). All assays were performed according to the manufacturer's recommendations and using their normal ranges.
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Measurement of hemostatic parameters and endothelial activation markers
Endothelial microparticle quantification
Endothelial microparticles (EMPs) were quantified by flow cytometry, using anti-CD146
(clone TEA1/34) and anti-CD105 (clone 1G2)-phycoerythrin (PE), anti-CD45-phycoerythin- 
Microparticles-linked procoagulant activity measurement
Microparticle-linked procoagulant activity was determined with the Zymuphen MP-activity kit (Hyphen BioMed, Neuville-sur-Oise, France). This method is based on a prothrombinase assay after microparticle capture on a micro-titration plate coated with streptavidin and biotinylated annexin V. Results were expressed as nanomolar phosphatidylserine equivalent by using a calibrator prepared from a washed and lysed platelet concentrate containing a known concentration of microparticles expressed in nM phosphatidylserine equivalent (nM eq PS).
Statistical analysis
Baseline patient characteristics and markers were compared according to anticoagulant therapy, using Fisher's exact test or the Wilcoxon rank sum test.
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Marker kinetics between baseline and week 11 were analyzed with mixed model analysis of variance. Two fixed effects modeled the variation between baseline and week 5 and between week 5 and week 11, and random subject effects were included to account for correlations between measurements in a given subject. Model goodness-of-fit was assessed by examining residuals. When necessary to obtain adequate models, data were log-transformed, or models with non constant residual variance were used. The hypothesis that marker kinetics are affected by anticoagulant therapy at baseline was tested by adding such an effect and its interaction with time in the models. If no interaction effect was found, only the test for the whole cohort is presented. All tests were two-sided, and p-values <0.05 were considered to indicate statistical significance. All analyses were performed using R 2.6.2 statistical software.
RESULTS
Patient characteristics
Twenty-three subjects with hemolytic PNH were analyzed. Fifteen patients had never had thrombotic events and did not receive anticoagulant therapy. Eight patients, seven of whom had a history of VTE, received anticoagulant therapy for VTE prophylaxis (1 fondaparinux, 1 danaparoid and 6 VKA). None of the characteristics listed in Table 1 differed between patients with and without anticoagulant therapy, apart from the prothrombin time, which was lower in patients on anticoagulants. No thrombosis occurred during eculizumab treatment.
Effect of eculizumab on intravascular hemolysis and thrombosis occurrence
Markers of thrombin generation and fibrinolysis
To assess the activation of coagulation, we studied F1+2, a direct marker of prothrombin activation to thrombin, D-dimers and P-AP complexes, as markers of reactional fibrinolysis induced by thrombin generation or by complement dysregulation.
Before eculizumab therapy, F1+2 plasma levels were increased (Table 2 ). Eculizumab treatment resulted in a significant decrease in F1+2 plasma levels (p=0.012) at week 5, which was sustained at week 11 ( Figure 1A ). Before eculizumab, F1+2 plasma levels were increased
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in the group without anticoagulants and normal in the group with anticoagulants (p=0.007 Figure 1A ).
Before eculizumab, D-dimer plasma levels were elevated (Table 2) , and eculizumab treatment resulted in a significant reduction in D-dimer plasma levels (p=0.01) at week 5, persisting at week 11 ( Figure 1B ). At baseline there was no significant difference according to the use of anticoagulant therapy (p=0.55), and the reduction in D-dimer plasma levels during eculizumab treatment was similar in the two groups (p=0.07).
Before eculizumab treatment P-AP complex plasma levels were normal, with no difference between the two groups ( Table 2) . Eculizumab treatment was associated with a significant decrease (p=0.0002) in plasma levels in the overall patient population at week 5, persisting at week 11 ( Figure 1C ).
Markers of endothelial cell activation
To evaluate the potential for endothelial cell activation and damage which could induce thrombosis, we studied several measures of endothelial function.
Before eculizumab, sVCAM-1 and vWF Ag were both above-normal range, while t-PA, PAI-1, sTM and sICAM-1 were normal. PAI-1 and t-PA were significantly higher in patients with anticoagulant therapy than in those without anticoagulant therapy (p=0.034 and p=0.013, respectively) ( Table 2 ). Eculizumab treatment was associated with significant decreases at weeks 5 and 11 in plasma levels of t-PA (p=0.0005) in two groups according to anticoagulant therapy, and in sVCAM-1 (p<0.0001) and vWF Ag (p=0.0047) in the overall © F e r r a t a S t o r t i F o u n d a t i o n group of patients (Figure 2 A-C); the effect on sVCAM-1 was more pronounced in the group with anticoagulant therapy (p=0.015) ( Figure 2B ). PAI-1, sTM and sICAM-1 plasma levels did not change during eculizumab treatment (data not shown).
Plasma levels of su-PAR were elevated in both groups before eculizumab treatment (Table 2) . Su-PAR kinetics differed between the groups (p=0.0004), with a significant decrease at week 5 in the anticoagulant group only (p=0.002), persisting at week 11; but su-PAR plasma levels remained elevated in both groups (data not shown).
Thus, endothelial cells were strongly activated and showed a potentially prothrombotic phenotype (elevated sVCAM-1 and vWF) in these patients with PNH. Eculizumab treatment significantly reduced the plasma levels of parameters associated with endothelial cell activation or damage (t-PA, sVCAM-1 and vWF).
TFPI
TFPI, the inhibitor of coagulation cascade initiation, is synthesized and released by endothelial cells.
Before treatment, total TFPI plasma levels were normal and free TFPI plasma levels were at the upper limit of normal (Table 2) . Eculizumab treatment was associated with significant decreases in both total TFPI (p=0.0008) and free TFPI (p=0.0013) plasma levels at week 5, persisting at week 11, with no difference according to anticoagulant therapy ( Figure 3 A-B ).
Microparticles
To further assess the activation and possible damage of endothelial cells, we measured endothelial microparticle release into the circulation ( Figure 4 ) and total microparticles shed from all cells exposing phosphatidylserine, which conferred a procoagulant activity.
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Before eculizumab, microparticles procoagulant activity, absolute plasma numbers of total EMPs and ICAM-1 (CD54)-expressing EMPs were elevated, while the percentage of ICAM-1+ EMPs was normal (Table 2) . No difference in these four parameters was found between the groups before eculizumab treatment (Table 2) , and eculizumab had no effect on these markers in either group (data not shown).
DISCUSSION
The pathogenesis of thrombotic complications in PNH is unclear. In particular, no deficiencies in antithrombin, protein C or protein S have been described in patients with PNH.
It was recently suggested that the most frequent symptoms of PNH are consistent with smooth muscle perturbation through the cell-free plasma hemoglobin and NO scavenging. The granulocyte clone size correlates with the risk of thrombosis in PNH. (5, 6) In our study, all the patients had large clones (> 57%; 20 patients > 70%) and were thus at a high thrombotic risk. As reported by Kakkar et al., patients with thrombosis and treated with anticoagulants decrease their F1+2 plasma levels. (19) This could explain why, in our study, the patients without anticoagulant therapy had higher F1+2 plasma levels than the 8 patients with anticoagulant therapy (7 with previous thrombosis, one on primary prophylaxis). In our study, before eculizumab treatment, the elevated F1+2 and D-dimer plasma levels in PNH patients (compared to the reference values) confirm the activation of both the coagulation and fibrinolytic system, (20) as observed in a previous study of small number of PNH patients.
This prothrombotic activity indicates that PNH patients, and particularly those not treated with anticoagulants, have significant activation of coagulation despite the absence of overt thrombosis. However, we found that plasma levels of PAP (a marker of plasmin generation)
were normal, suggesting that fibrinolytic system activation was impaired. The increase in © F e r r a t a S t o r t i F o u n d a t i o n su-PAR, also observed in previous studies, (22, 23) Interestingly, eculizumab significantly reduced the plasma levels of F1+2, D-dimers and P-AP complexes during the induction phase (week 5) and during chronic treatment (week 11), and even at week 47 in the 9 patients tested (data not shown). These results indicate a decrease in coagulation activation and in reactional fibrinolysis during eculizumab therapy.
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Patients receiving anticoagulant treatment after a thrombotic event had even lower F1+2 plasma levels probably related to the anticoagulant treatment itself.
Recently, Weitz et al. reported, in an abstract form, that eculizumab reduced D-dimer and thrombin-antithrombin complex levels, independently of hemolysis suppression based on LDH assay. This reduction correlated with a decrease in IL-6, an inflammatory maker. (27) However, this effect on IL-6 could also be related to a decrease in IL-6 production by endothelial cells due to decreased thrombin generation. (28) . In our study, LDH levels normalized in all patients after the eculizumab induction phase. The lack of correlation, observed by Weitz et al., (27) between decreased LDH and thrombin generation suggests that the potential reduction in clinical thrombosis by eculizumab is not only due to a decrease in hemolysis leading to the hypothesis of the pathogenic role of the endothelium in PNH-related thromboembolism.
The fact that t-PA was significantly reduced by eculizumab treatment while sICAM-1 and sTM plasma levels were unaffected does not rule out a possible effect of eculizumab treatment on endothelial cell activation; indeed sICAM-1 is ubiquitous and sTM levels are not modified in the absence of inflammation.
Total and free TFPI were significantly reduced by eculizumab treatment; however, the levels of free TFPI, the only active form in anticoagulation, remained over the 5 th percentile and are thus not associated with an increased risk of thrombosis.
(29) Low molecular weight heparin is known to enhance TFPI plasma levels, (30) but only one of our patients received this treatment.
Su-PAR levels were substantially above the upper limit but eculizumab reduced plasma su-PAR levels only in patients with concomitant anticoagulant treatment. In this group F1+2 levels and, thus, thrombin generation were lower (see above). Thus, platelet activation due to thrombin must be lower; and, as reported recently by Sloand et al., part of su-PAR in PNH
patients is released from activated platelets.
(31) Moreover, the decrease in hemolysis, reduces ADP secretion and NO-depletion, and, thus, platelet activation.
Among all the tested markers, D-dimers, which decreased during eculizumab treatment and can be routinely measured, could be used in future to perform prospective, multi-center study to detect PNH patients with high thrombotic risk. Unfortunately, apart from vWF antigen assay, specific markers of endothelial activation are not routine test.
Importantly, terminal complement inhibition with eculizumab significantly reduced plasma levels of endothelial activation markers during the induction phase. This decrease was sustained in the maintenance phase. These effects may be due partly to an eculizumabmediated improvement of hemolysis, which had a positive impact on hemostasis via reduction in NO-depletion; (32) they could also be due to the decrease in complement-mediated pathological activation of endothelial cells. Indeed, several findings support pathological endothelial cell activation and/or activation of a pathological PNH phenotype endothelial cell:
1. VWF and sVCAM-1 plasma levels were elevated in patients with PNH, and were significantly reduced during eculizumab treatment. Previous studies of cultured normal endothelial cells showed that complement proteins C5b-C9 induce vWF secretion, (33, 343) increase VCAM-1 expression, (35) and trigger the release of procoagulant microparticles.
The membrane attack complex also induces endothelial cells to produce and secrete IL-1, which can stimulate endothelial cells, in an autocrine or paracrine fashion, to generate the activated phenotype.
2. TFPI, the main source of which is the endothelium, involves a GPI mediated membrane anchorage in localizing to the surface of endothelial cells. plasma levels of total TFPI were reduced in PNH patients, while free TFPI levels were normal.
3. The identification of a new thrombophilic disease in which an autosomal recessive inherited GPI deficiency is not associated with apparent hemolysis supports the contribution of a non-hemolytic mechanism to thrombosis in a context of GPI deficiency.
4. We found (see Supplementary Data) that ECFCs isolated from peripheral blood of a PNH patient and a healthy control showed that the patient had a two and three populations of ECFCs based on CD55 and CD59 expression, respectively, possibly corresponding to the presence of a pathological endothelial cell population. This defect of GPI-anchored protein expression on ECFCs suggests that endothelial cells could be affected by a PIG-A mutation.
In this case, eculizumab might prevent clinical thrombosis not only by inhibiting hemolysis and subsequent NO-depletion, but also by protecting pathological endothelial cells from complement activation. (13) To our knowledge there are no reported attempts to identify endothelial cells with the PNH phenotype, probably due to the large amount of blood necessary for such assay. Further investigations with more patients are obviously necessary to confirm this hypothesis.
In conclusion, we demonstrate an endothelial dysfunction in PNH, which could be due to NO-depletion via hemolysis and/or platelet dysfunction; however our results suggest a possible contribution of endothelial cell activation and dysfunction to the increased risk of thrombosis in PNH. Treatment with the terminal complement inhibitor eculizumab led to a significant and sustained decrease in activation of both the plasmatic hemostatic system and of the endothelium. This biological effect may help to explain the observed clinical benefit of © F e r r a t a S t o r t i F o u n d a t i o n eculizumab to reduce thrombosis in patients with PNH. (13) Our results thus suggest a new role of endothelial cells in the occurrence of VTE in this setting. Interestingly, while the endothelial cell has never been studied directly in PNH patients, it may not be coincidental that we found a decrease in endothelial cells activation during treatment with eculizumab and a possible direct impairment of endothelial cells in GPI-anchored proteins. A prospective study with more patients is underway to confirm this apparent key role of endothelial cells in thrombosis of PNH-associated thrombosis. © F e r r a t a S t o r t i F o u n d a t i o n © F e r r a t a S t o r t i F o u n d a t i o n © F e r r a t a S t o r t i F o u n d a t i o n Table 1 . Patients characteristics at baseline.
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